Last reviewed · How we verify
ELDECALCITOL
At a glance
| Generic name | ELDECALCITOL |
|---|---|
| Sponsor | Chugai Pharmaceutical Co., Ltd |
| Target | Vitamin D3 receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Osteoporosis
Common side effects
Key clinical trials
- Study on the Intervention Effect of Denosumab on High-Risk Patients With Osteoporotic Fractures in Type 2 Diabetes (NA)
- Efficacy and Safety of Combination Denosumab With Eldecalcitol for Postmenopausal Women With Osteoporosis.(ESCORT) (PHASE4)
- Clinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia (PHASE4)
- Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis (PHASE4)
- A Study on the Prevention and Treatment of GIOP With Eldecalcitol (PHASE4)
- Post-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients With Postmenopausal Osteoporosis
- Bioequivalence Study of Eldecalcitol Soft Capsule in Healthy Chinese Subjects (PHASE1)
- The Effectiveness of Eldecalcitol in the Bisphosphonate Non-respondered-patients With Osteoporosis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ELDECALCITOL CI brief — competitive landscape report
- ELDECALCITOL updates RSS · CI watch RSS
- Chugai Pharmaceutical Co., Ltd portfolio CI